Quest Diagnostics Incorporated (DGX)
| Market Cap | 25.68B +26.9% |
| Revenue (ttm) | 11.56B +9.9% |
| Net Income | 1.06B +11.8% |
| EPS | 9.42 +12.8% |
| Shares Out | 110.37M |
| PE Ratio | 24.70 |
| Forward PE | 20.31 |
| Dividend | $3.44 (1.48%) |
| Ex-Dividend Date | Oct 6, 2026 |
| Volume | 865,230 |
| Open | 228.66 |
| Previous Close | 230.97 |
| Day's Range | 228.66 - 234.64 |
| 52-Week Range | 171.18 - 248.84 |
| Beta | 0.54 |
| Analysts | Buy |
| Price Target | 248.80 (+6.95%) |
| Earnings Date | Oct 22, 2026 |
About DGX
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceu... [Read more]
Financial Performance
In 2025, Quest Diagnostics's revenue was $11.04 billion, an increase of 11.78% compared to the previous year's $9.87 billion. Earnings were $988.00 million, an increase of 14.09%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for DGX stock is "Buy." The 12-month stock price target is $248.8, which is an increase of 6.95% from the latest price.
News
Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials
Test showed 100% specificity, with no false-positive results in the cohort, at both 3- and 5-year follow-up, and sensitivity of 100% and 83.3%, respectively, for predicting disease recurrence SECAUCUS...
Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026
SECAUCUS, N.J., Sept. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its third quarter 2026 finan...
Nearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
Study published in JAMA Network Open of over 193,000 patients nationwide reveals that individuals with evidence of exposure to Borrelia burgdorferi, the bacterium that causes Lyme disease, are more th...
Nine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics
75% of registered voters surveyed call diagnostic testing "very important" to their care, and a bipartisan majority wants Congress to pass the RESULTS Act before additional Medicare cuts are schedule...
Quest Diagnostics Transcript: 2026 Global Healthcare Conference
Revenue and earnings growth have outpaced long-term plans, driven by organic expansion, partnerships, and a rapidly growing consumer health segment. Strategic focus has shifted from M&A to integration and partnerships, with new executive talent and board expertise supporting this evolution. Regulatory uncertainty around PAMA remains, but advocacy for legislative solutions continues.
Quest Diagnostics Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
2026 guidance was raised on strong first-half results, with consumer and partnership growth driving performance. Margin expansion is expected as integration costs subside and advanced diagnostics, consumer, and digital partnerships accelerate. Market share gains and robust M&A activity support a positive long-term outlook.
Apple Health app Users to be Able to Order Labs from Quest Diagnostics
Coming later this year, Apple Health app users will be able to conveniently and securely purchase and receive results of Quest's biomarker lab testing directly in the app SECAUCUS, N.J., Sept. 9, 2026...
Quest Diagnostics to Speak at the Baird 2026 Global Healthcare Conference
SECAUCUS, N.J., Aug. 25, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak...
Humanity Brings Biological Age Analysis to the U.S. Through questhealth.com
Individuals in the U.S. can now add Humanity Biological Age's lab-informed insights to select health profile tests purchased through Quest's consumer-initiated testing platform LONDON, Aug. 25, 2026 /...
Quest Diagnostics to Speak at the Morgan Stanley 24th Annual Global Healthcare Conference
SECAUCUS, N.J., Aug. 24, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive Vice President & Chief Financ...
Quest Diagnostics to Offer FDA-Cleared Roche pTau217 Blood Test to Assess Alzheimer's Disease Pathology
Test to join the company's expansive portfolio of Quest AD-Detect® blood tests for assessing symptomatic patients Quest also launching a new multi-biomarker AD-Detect® lab-developed blood test with lo...
WHOOP Makes Advanced Labs Available Without a Wearable Membership
BOSTON--(BUSINESS WIRE)--WHOOP, the human performance brand, today announced it is expanding access to proactive health, adding Galleri®, GRAIL's multi-cancer early detection test and, for the first t...
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J., Aug. 12, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividend...
Quest Diagnostics typically performs between 30 and 40 cyclospora tests a day. Now it's processing more than 1,500.
Samples—and a certain stink—are accumulating at Quest Diagnostics thanks to the cyclosporiasis outbreak. “You get used to it.
Quest Diagnostics CEO: AI is helping patients understand their doctors
Quest Diagnostics president and CEO Jim Davis discusses how his company is implementing AI to help its patients on 'The Claman Countdown.' #fox #media #breakingnews #us #usa #new #news #breaking #foxb...
Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics
Largest nationally representative study finds 12% of patients positive for bacterial vaginosis are infected with at least one STI, such as chlamydia or gonorrhea SECAUCUS, N.J., July 30, 2026 /PRNewsw...
Quest Diagnostics Earnings Call Transcript: Q2 2026
Q2 2026 saw over 10% revenue growth and a 19% rise in adjusted EPS, driven by strong demand across all channels and operational improvements. Full-year guidance was raised, with robust performance in advanced diagnostics and stable financial metrics.
Quest Diagnostics Earnings release: Q2 2026
Quest Diagnostics released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Quest Diagnostics Slides: Q2 2026
Quest Diagnostics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 23, 2026.
Quest Diagnostics Quarterly report: Q2 2026
Quest Diagnostics has published its Q2 2026 quarterly earnings report on July 23, 2026.
Quest Diagnostics raises annual forecast on testing demand
Quest Diagnostics on Thursday raised its full-year profit forecast, after demand for routine diagnostic testing helped the company beat second-quarter estimates.
Quest Diagnostics Reports Second Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
Second quarter revenues of $3.04 billion, up 10.2% from 2025, with 10.0% organic revenue growth Second quarter reported diluted earnings per share ("EPS") of $2.84, up 15.0% from 2025; and adjusted di...
Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI
American Oncology Network (AON) and other community oncology providers launching now as part of a pilot program that provides access to Haystack MRD SECAUCUS, N.J., July 8, 2026 /PRNewswire/ -- Quest ...
Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing
Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancers SECAUCUS, N.J., June 24, 2026 /P...
UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics
Published in Nature Communications, the new study finds that nearly 70% of a common bacterial strain that causes urinary tract infections, pneumonia and wound infections was non-susceptible to the thr...